HK:6855 Stock Latest News

Ascentage Pharma: Buy Rating Reiterated on Advancing CML/ALL Pipeline and DCF-Supported Unchanged $48 Price Target

PremiumRatings

7d ago

Ascentage Pharma Adds Executive Equity Grants to AGM Agenda and Updates Proxy Process

PremiumCompany Announcements

21d ago

Ascentage Pharma Sets AGM to Approve 2025 Accounts, Board Mandates and Share Issue Authority

PremiumCompany Announcements

23d ago

Ascentage Pharma initiated with a Buy at Deutsche Bank

PremiumThe Fly

27d ago

PremiumCompany AnnouncementsAscentage Pharma to Showcase Six Cancer Drug Studies at 2026 ASCO Meeting

30d ago

Ascentage Pharma Grants New RSUs to Top Executives Under 2022 Incentive Scheme

Company Announcements

Ascentage Pharma Grants New RSUs to Top Executives Under 2022 Incentive Scheme

1M ago

Ascentage Pharma Showcases Promising Combination Oncology Data at AACR 2026

Company Announcements

Ascentage Pharma Showcases Promising Combination Oncology Data at AACR 2026

1M ago

Ascentage Pharma management to meet with Piper Sandler

PremiumThe Fly

1M ago

Ascentage Pharma management to meet with BTIG

PremiumThe Fly

2M ago

Ascentage Pharma Relocates Hong Kong Principal Office and Highlights Global Governance Standards

PremiumCompany Announcements

2M ago

Ascentage Pharma Advances Pivotal APG-2575 Trial in Difficult-to-Treat CLL/SLL

PremiumCompany Announcements

2M ago

PremiumCompany AnnouncementsAscentage Pharma Ramps Up Sales, Dual Listing and Late-Stage Oncology Pipeline in 2025

2M ago

Ascentage Pharma Showcases Four Preclinical Cancer Programs at 2026 AACR Meeting

Company Announcements

Ascentage Pharma Showcases Four Preclinical Cancer Programs at 2026 AACR Meeting

2M ago

Ascentage Pharma Sets March Board Meeting to Approve 2025 Results and Consider Final Dividend

Company Announcements

Ascentage Pharma Sets March Board Meeting to Approve 2025 Results and Consider Final Dividend

2M ago

Ascentage Pharma initiated with a Buy at BTIG

PremiumThe Fly

2M ago

Ascentage Pharma: Undervalued Long-Term Oncology Leader Backed by Late-Stage Assets Olverembatinib and Lisaftoclax

PremiumRatings

2M ago

Ascentage Pharma Launches New Phase I Blood Cancer Trial That Could Shape Its Pipeline Outlook

PremiumCompany Announcements

3M ago

Ascentage Pharma announces IND clearance by the China CDE for APG-3288

PremiumThe Fly

3M ago

PremiumThe FlyAscentage Pharma initiated with a Buy at Rodman & Renshaw

4M ago

Ascentage Pharma’s APG-3288 receives IND clearance from FDA

The Fly

Ascentage Pharma’s APG-3288 receives IND clearance from FDA

4M ago

Ascentage Pharma Enhances Board Structure, Sets Shareholder Vote on Equity Grant

Company Announcements

Ascentage Pharma Enhances Board Structure, Sets Shareholder Vote on Equity Grant

5M ago